Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Jim M. Koeller, Jennifer M. Whitehead, Kathleen Franklin, Paromita Datta, Munaf Alkadimi, Lance Brannman, Ion Cotarla, Andrew J. Frankart, Tiernan Mulrooney, Xavier Jones, Christopher R. Frei

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population. Materials and Methods: This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected. Results: A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P =. 25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P =. 08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P =. 03) and less likely to experience pneumonitis (7% vs. 14%, P <. 01). Conclusion: Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.

Original languageEnglish (US)
Pages (from-to)804-811
Number of pages8
JournalOncologist
Volume28
Issue number9
DOIs
StatePublished - Sep 2023
Externally publishedYes

Keywords

  • durvalumab
  • health disparity
  • health equity
  • immunotherapy
  • lung cancer

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration'. Together they form a unique fingerprint.

Cite this